SCHEMBL6419900

SCHEMBL6419900

C#Cc1ccn2cc(C(=O)N[C@@H]3C[C@@H]4CCN(C4)C3)ccc12

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 14/20 0.56
HPGDS O60760 1/20 0.33
CTSB P07858 3/20 0.33
CTSK P43235 3/20 0.33
CTSS P25774 1/20 0.33
CTSC P53634 1/20 0.33
HTR3E A5X5Y0 1/20 0.32
HTR3B O95264 1/20 0.32
ALOX15 P16050 1/20 0.32
TSHR P16473 1/20 0.32
HTR3A P46098 1/20 0.32
HTR3D Q70Z44 1/20 0.32
HTR3C Q8WXA8 1/20 0.32
MAPT P10636 1/20 0.32
RAB9A P51151 1/20 0.32
CTSL P07711 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6419897 1.00 CHRNA7 (0.56) CHRNA7HPGDSCTSBCTSKCTSS
SCHEMBL6419917 1.00 CHRNA7 (0.56) CHRNA7HPGDSCTSBCTSKCTSS
SCHEMBL6412331 0.90 CHRNA7 (0.56) CHRNA7CTSBCTSKCTSSCTSC
SCHEMBL6412320 0.90 CHRNA7 (0.56) CHRNA7CTSBCTSKCTSSCTSC
SCHEMBL6419886 0.90 CHRNA7 (0.56) CHRNA7CTSBCTSKCTSSCTSC
SCHEMBL6412200 0.87 CHRNA7 (0.55) CHRNA7CTSBCTSKCTSL
SCHEMBL6412193 0.87 CHRNA7 (0.55) CHRNA7CTSBCTSKCTSL
SCHEMBL6414816 0.87 CHRNA7 (0.55) CHRNA7CTSBCTSKCTSL
SCHEMBL6418131 0.84 CHRNA7 (0.59) CHRNA7HPGDSHTR3EHTR3BALOX15
SCHEMBL6416573 0.84 CHRNA7 (0.65) CHRNA7HTR3EHTR3BALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050215584-A1 Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease PFIZER INC 2005-09-29 US claimed
US-20030236264-A1 Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-12-25 US claimed
US-20050215584-A1 Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease PFIZER INC 2005-09-29 US disclosed
US-6858613-B2 Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease PFIZER INC. (US) 2005-02-22 US disclosed
US-20030236264-A1 Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236264-A1 Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease NAT1, CYP11B1, COASY CHRNA7 1475/4885HPGDS 2142/4885CTSB 1436/4885
US-20050215584-A1 Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease CHRNA7, UGT2B7, CHRNA5 CHRNA7 1/4885HPGDS 3247/4885CTSB 1247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.